Impact of Amide Functionality in the Side Chain of 5th Residue of Multivalent Ligands Acting as MOR/DOR Agonist and Neurokinin 1 Receptor (Nk1) Antagonist

Technology #ua15-052

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Aswini Giri
Assistant Research Scientist, Chemistry & Biochemistry
Victor Hruby
Regents Professor Emeritus, Chemistry & Biochemistry
Managed By
Paul Eynott
Sr. Licensing Manager (520) 621-2878

Tech ID: UA15-052

 

Background:

Current chronic pain treatments, such as opioids, typically target the mu opioid receptor (MOR), which can leave patients with unwanted side effects. These drugs can also lead to drug dependency and drug interactions. While therapies exist to target other receptors, such as the delta opioid receptor (DOR) which often have fewer negative effects, the pain may not diminish as well as with a drug targeting MOR.

 

Studies show that a combination of MOR/DOR Agonist and Neurokinin 1 Receptor (NK1) Antagonist can have synergistic effects in managing chronic pain where there is a higher release of neurotransmitters, such as substance P. This invention uses this concept of multiple analgesic targets by using two potent multifunctional ligands having bioactivity at MOR/DOR and NK1 receptor.

 

Invention:

A single molecule targeting MOR/DOR Agonist and NK1 Receptors Antagonist and having better metabolic absorption, distribution, metabolism, and excretion (ADME) and pharmacological properties than current treatments.

 

Advantages:

  • Fewer side effects
  • Reduced chance of drug interactions
  • Reduced risk of drug tolerance and drug abuse
  • Better ADME

 

Applications:

  • Chronic pain treatment, including acute pain and neuropathic pain

 

Patent Status: Provisional Patent Application

 

Lead Inventors: Aswini Giri, Dr. Victor Hruby

 

 

Licensing Manager:

Rakhi Gibbons

RakhiG@TLA.arizona.edu

(520) 626-6695